ReviewMolecules (Basel, Switzerland)2021
How the Chemical Properties of GBCAs Influence Their Safety Profiles In Vivo.
Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 26 citations in OpenAlex.
- Preserving Gadolinium Speciation in Environmental Waters: Establishing Hold Times and Storage Protocols for Reliable Analysis.ACS ES&T water · 2026Article
- Gadolinium-Based Contrast Agents and the Theater of Safety.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- In vivo membrane engineering traps Gd-based MRI contrast agents for detecting microhepatocellular carcinoma.Science advances · 2026Article
- Synthesis and Characterization of a Novel Biphenol-Based Gadolinium Complex for Encapsulation in Human Red Blood Cells.International journal of molecular sciences · 2026Article
- Article
- Purification and pharmacokinetic study of gadoxetate isomers for enhanced rabbit liver MR imaging.PloS one · 2026Article
- Identifying a potential role of immune cells in gadolinium deposition within the brain.Fluids and barriers of the CNS · 2025Article
- Early endolysosomal dysfunction is a contributing factor to gadolinium-based contrast agent mouse renal proximal tubule epithelial cell injury.Cell biology and toxicology · 2025Article
- Electrochemical Method for the Design of New Possible Gadolinium-Based Contrast Agents.Nanomaterials (Basel, Switzerland) · 2024Article
- Chirality of New Drug Approvals (2013-2022): Trends and Perspectives.Journal of medicinal chemistry · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
The extracellular class of gadolinium-based contrast agents (GBCAs) is an essential tool for clinical diagnosis and disease management. In order to better understand the issues associated with GBCA administration and gadolinium retention and deposition in the human brain, the chemical properties of GBCAs such as relative thermodynamic and kinetic stabilities and their likelihood of forming gadolinium deposits in vivo will be reviewed. The chemical form of gadolinium causing the hyperintensity is an open question. On the basis of estimates of total gadolinium concentration present, it is highly unlikely that the intact chelate is causing the
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.